Literature DB >> 14576338

Membrane restraint of estrogen receptor alpha enhances estrogen-dependent nuclear localization and genomic function.

Yun Xu1, Richard J Traystman, Patricia D Hurn, Michael M Wang.   

Abstract

Estrogen receptor (ER) alpha localizes to both the nucleus and the plasma membrane, mediating estrogen-dependent genomic and nongenomic signaling, respectively. In some cells, ERalpha appears to be excluded from the nucleus, and it is unclear whether genomic signaling takes place. The purpose of this study was to determine whether membrane-associated ERalpha is capable of genomic signaling, or whether this pool of receptors strictly serves membrane-mediated signaling. ERalpha fused to the C-terminal cytoplasmic tail of bovine rhodopsin (Rh-ERalpha) activates ER response element-dependent transcription only in the presence of estrogen; the activity is antagonized by the estrogen antagonist ICI 182,780 and by the dominant-negative mutant of ERalpha and is unaffected by inhibitors of MAPKs and Akt signaling, indicating that this was due to direct genomic action. The activity of Rh-ERalpha containing the activating Y537S mutation was also estrogen dependent, suggesting that estrogen gated the entry of Rh-ERalpha into the nucleus. Indeed, cell fractionation studies demonstrated that Rh-ERalpha protein, in contrast to ERalpha that was nuclear at baseline, was excluded from the nucleus in the absence of hormone, and localized to the inner nuclear membrane on incubation with estrogen. These data demonstrate that membrane tethered ERalpha is capable of nuclear function and that its transcriptional activity is regulated by hormone-dependent entry into the inner nuclear membrane. Furthermore, these experiments provide evidence that under certain circumstances, membrane proteins are capable of nuclear function without detectable nucleoplasmic localization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576338     DOI: 10.1210/me.2003-0262

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  8 in total

1.  p150/glued modifies nuclear estrogen receptor function.

Authors:  Soo Jung Lee; Christina Chae; Michael M Wang
Journal:  Mol Endocrinol       Date:  2009-02-19

2.  Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells.

Authors:  A E Richardson; N Hamilton; W Davis; C Brito; D De León
Journal:  Growth Factors       Date:  2011-03-16       Impact factor: 2.511

Review 3.  Mechanisms of gender-linked ischemic brain injury.

Authors:  Mingyue Liu; Suzan Dziennis; Patricia D Hurn; Nabil J Alkayed
Journal:  Restor Neurol Neurosci       Date:  2009       Impact factor: 2.406

4.  17beta-estradiol protects against hypoxic/ischemic white matter damage in the neonatal rat brain.

Authors:  Bettina Gerstner; Joan Lee; Tara M DeSilva; Frances E Jensen; Joseph J Volpe; Paul A Rosenberg
Journal:  J Neurosci Res       Date:  2009-07       Impact factor: 4.164

Review 5.  Dynamic regulation of estrogen receptor-alpha gene expression in the brain: a role for promoter methylation?

Authors:  Melinda E Wilson; Jenne M Westberry; Amanda K Prewitt
Journal:  Front Neuroendocrinol       Date:  2008-03-13       Impact factor: 8.606

Review 6.  Membrane estradiol signaling in the brain.

Authors:  Paul Micevych; Reymundo Dominguez
Journal:  Front Neuroendocrinol       Date:  2009-05-04       Impact factor: 8.606

7.  Diammonium glycyrrhizinate upregulates PGC-1α and protects against Aβ1-42-induced neurotoxicity.

Authors:  Xiaolei Zhu; Cong Chen; Dan Ye; Dening Guan; Lan Ye; Jiali Jin; Hui Zhao; Yanting Chen; Zhongyuan Wang; Xin Wang; Yun Xu
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

Review 8.  Estrogens in Human Male Gonadotropin Secretion and Testicular Physiology From Infancy to Late Puberty.

Authors:  Gabriela Guercio; Nora Saraco; Mariana Costanzo; Roxana Marino; Pablo Ramirez; Esperanza Berensztein; Marco A Rivarola; Alicia Belgorosky
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-25       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.